View CME-certified poster presentations and downloadable slides covering the most up-to-date clinical trial data on RCC from the 2018 European Oncology Congress in Munich.
0.75 AMA PRA Category 1 Credit(s)™
Apr 15, 2019
Apr 15, 2020
Abstract #863O: Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results
Featured Expert: Marine Gross-Goupil, MD
Abstract #LBA6_PR: JAVELIN Renal 101: a randomized, phase 3 study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)
Featured Expert: Manuela Schmidinger, MD
Abstract #874P: Treatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis
Featured Expert: David McDermott, MD
Abstract #875P: Characterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (aRCC): CheckMate 214
Featured Expert: Brian I. Rini, MD
Marine Gross-Goupil, MDCHU Bordeaux Hopital St. André
David McDermott, MDBeth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Brian I. Rini, MDCleveland Clinic
Cleveland, Ohio, United States
Manuela Schmidinger, MDMedical University of Vienna
This activity is specifically designed for physicians, nurses, and other clinicians who are cancer specialists.
After successful completion of this educational activity, participants should be able to:
- Identify clinical trial data presented at 2018 European Oncology Congress in Munich
- Incorporate new findings presented in Munich into patient treatment regimens, where applicable
This educational activity is supported by grants from Bayer HealthCare Pharmaceuticals, Inc.; Bristol-Myers Squibb; and Merck and Co, Inc.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
Method of Participation
Estimated time to complete activity: 0.75 hours
To contact Postgraduate Institute for Medicine please visit www.pimed.com.
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Gross-Goupil has disclosed that she has received consulting fees from Bristol-Myers Squibb, Ipsen, Pfizer, and Roche. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr McDermott has disclosed that he has received consulting fees from Bristol-Myers Squibb. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Rini has disclosed that he has received consulting fees from Bristol-Myers Squibb, Peloton, and Pfizer. He also disclosed independent contracting for Bristol-Myers Squibb, Merck, Peloton, and Pfizer. He further disclosed membership on advisory committees or review panels for Bristol-Myers Squibb, Merck, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Schmidinger has disclosed that she has a board membership with ESMO. She also disclosed receipt of consulting fees from and membership on advisory committees or review panels for Astellas, Bristol-Myers Squibb, Eisai, Eusa, Exelixis, Ipsen, Novartis, Pfizer, and Roche. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.
The employees of prIME Oncology have disclosed:
- Angela Zimmermann, PhD (scientific content manager) – worked on non–CME certified projects in the last 12 months supported by AstraZeneca, Merck, Novartis, and Pfizer
- Susan McKinney (editorial content reviewer) – no relevant financial relationships
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.